Carregant...
HOUT-16. THE COST EFFECTIVENESS OF TUMOR TREATING FIELDS TREATMENT FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA BASED ON THE EF-14 TRIAL
BACKGROUND: With the EF-14 Trial reporting a 5-year survival rate of 13% for newly diagnosed Glioblastoma (GBM) patients treated with TTFields and maintenance temozolomide (TMZ) chemotherapy, a relevant number of patients will become long-term survivors. The impact on resource utilization from a hea...
Guardat en:
| Publicat a: | Neuro Oncol |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Oxford University Press
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6217126/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.484 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|